Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.09. | Vivos Therapeutics, Inc: Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device | 141 | GlobeNewswire (Europe) | LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development... ► Artikel lesen | |
VIVOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
17.09. | Vivos Therapeutics, Inc: Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment | 143 | GlobeNewswire (Europe) | LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development... ► Artikel lesen | |
12.09. | Vivos Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.08. | Vivos Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
20.08. | Vivos Therapeutics GAAP EPS of -$0.55, revenue of $3.82M | 3 | Seeking Alpha | ||
19.08. | Vivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update | 211 | GlobeNewswire (Europe) | Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments... ► Artikel lesen | |
19.08. | Vivos Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
30.07. | Vivos Therapeutics appoints two executives to support growth strategy | 3 | Investing.com | ||
30.07. | Vivos Therapeutics, Inc: Vivos Therapeutics Adds to Management Team to Support Expansion and Growth | 1 | GlobeNewswire (USA) | ||
01.07. | Vivos Therapeutics stock soars after Medicare approves VidaSleep oral appliance | 1 | Investing.com | ||
01.07. | Vivos Therapeutics, Inc: Vivos Therapeutics Receives Medicare Approval for VidaSleep Oral Appliance | 1 | GlobeNewswire (USA) | ||
26.06. | Vivos Therapeutics Stock Climbs 9% On Positive Pediatric Sleep Apnea Study | - | RTTNews | ||
26.06. | Vivos Therapeutics, Inc: New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children | 1 | GlobeNewswire (USA) | ||
11.06. | Vivos Therapeutics Finalizes Acquisition Of The Sleep Center Of Nevada | 1 | RTTNews | ||
11.06. | Vivos Therapeutics, Inc: Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada | 286 | GlobeNewswire (Europe) | Transaction brings OSA diagnostic revenue to Vivos, plus Vivos' highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area Transaction also completes... ► Artikel lesen | |
06.06. | Vivos Therapeutics ernennt Baker Tilly nach Fusion zum neuen Wirtschaftsprüfer | 1 | Investing.com Deutsch | ||
06.06. | Vivos Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
23.05. | Vivos Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
16.05. | Vivos Therapeutics GAAP EPS of -$0.45 misses by $0.10, revenue of $3.02M misses by $1.18M | 11 | Seeking Alpha | ||
16.05. | Vivos Therapeutics signals transformative growth with SCN acquisition and expects positive cash flow by end of 2025 | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ECKERT & ZIEGLER | 17,440 | +3,13 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
SERNOVA BIOTHERAPEUTICS | 0,102 | -4,67 % | Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focused... ► Artikel lesen | |
SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB erweitert Investitionen in Italien mit Eröffnung eines neuen Vorzeige-Medizinzentrums in Florenz | EQS-News: SYNLAB
/ Schlagwort(e): Expansion
SYNLAB erweitert Investitionen in Italien mit Eröffnung eines neuen Vorzeige-Medizinzentrums in Florenz
09.10.2025 / 15:00 CET/CEST
Für... ► Artikel lesen | |
NUGEN MEDICAL DEVICES | 0,030 | +3,47 % | NuGen Medical: Kurs explodiert nach wichtiger News! | ||
PLUS THERAPEUTICS | 0,575 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer | HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed... ► Artikel lesen | |
CARDINAL HEALTH | 135,35 | +0,15 % | Cardinal Health's Q1 2026 Earnings: What to Expect | ||
ATOSSA THERAPEUTICS | 0,875 | +1,27 % | Atossa Therapeutics Inc: Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness | 25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem shareholders reject merger with Aditxt, company pivots to seek listing | ||
UNIDOC HEALTH | 0,124 | -3,89 % | UniDoc Health Corp.: UniDoc Announces Amended LIFE Offering | THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / October 17, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 48,370 | +1,23 % | AKTIEN IM FOKUS: Siemens, Siemens Healthineers und Energy unter Druck | FRANKFURT (dpa-AFX) - Die drei Aktien aus dem Umfeld von Siemens haben am Dienstag zu den Verlierern in einem schwachen Dax gezählt. Die Papiere von Siemens verloren zuletzt rund 2,9 Prozent und die... ► Artikel lesen | |
FRESENIUS | 48,200 | +1,18 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Fresenius nach einem Gespräch mit Konzernchef Michael Sen auf "Overweight" mit einem Kursziel von 49,10 Euro belassen. Am interessantesten... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 46,600 | +0,43 % | ROUNDUP/Aktien Frankfurt Eröffnung: Im Plus - Hoffen auf nächste US-Zinssenkung | FRANKFURT (dpa-AFX) - Mit moderaten Gewinnen am Mittwoch hat sich im Dax das Auf und Ab auf hohem Niveau fortgesetzt. Hoffnungen auf sinkende Zinsen in den USA stützen. Zudem stellen sich in der politischen... ► Artikel lesen | |
BRIGHTSPRING HEALTH SERVICES | 30,470 | 0,00 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
ALIGNMENT HEALTHCARE | 17,390 | +1,58 % | Alignment Healthcare USA, LLC: Alignment Health Plan and Intermountain Health Launch $0-Premium, 5-star Medicare Advantage Plan for Nevada Seniors | ||
CARL ZEISS MEDITEC | 47,100 | +3,15 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Carl Zeiss Meditec auf "Underweight" mit einem Kursziel von 35,10 Euro belassen. Anchal Verma sieht in einer am Freitag vorliegenden... ► Artikel lesen |